Primary myelofibrosis (PMF), a type of bone marrow cancer that is very rare but painful, disrupts the body’s normal production of blood cells by causing extensive dissection in the bone marrow. Unfortunately, there are not many treatment options available, with most of them discounted. The only therapeutic treatment is cell gas transplantation, where many patients are not eligible.
A new study by researchers at Boston University School of Medicine (BUSM) led by corresponding author Katya Ravid, DSc, has found that the drugs PXS-LOX_1 and PXS-LOX_2 are capable of advancing PMF disease slow down in experimental models.
According to Ravid, professor of medicine and biochemistry at BUSM and professor of biology at Boston University, these drugs are unique in that they are able to inhibit their target, a protein called lysyl oxidase, with an unprecedented combination of uniqueness and strength. drugs. These conventional findings build on previous findings and publications by Ravid and his group, showing which specific proteins in the bone marrow cause the devastating effect seen in PMF.
Three experimental models were used for this study: the first group was normal, and the other two had gene changes that led them to develop cancer in their bone marrow. All three groups were assigned the drug PXS-LOX_1. Although it did not cause significant changes in the normal models, it did reduce the severity of bone marrow cancer symptoms in all modified groups. In a separate experiment, PXS-LOX_2 was assigned to a standard set and one of the genetically modified groups. This test did not cause any change in the normal group, but a reduction in the severity of the cancer symptoms of the modified models.
Ravid, believes that these decisions are important because they represent a potential modern treatment pathway for PMF, as there are currently no drugs available that will combat it. bone marrow matrix proteins in the way that PXS-LOX_1 and PXS-LOX_2 fight it. “If these drugs are eventually approved for human use, they could help slow the progression of cancer and reduce the painful symptoms of the disease.”
The researchers hope this study will contribute to the development of novel treatment options for primary myelofibrosis. Based on this study, Biotech Pharmaxis Australia has initiated Phase 1-2 clinical trials in humans.
These findings will appear online in the journal Archives of Gas Cell and Medicine.
Source:
Boston University School of Medicine
Magazine Reference:
Piasecki, A., et al. (2020) Lysyl oxidase Inhibition in Primary Myelofibrosis: A Regenerative Strategy. Archives of Gas Cell and Medicine. doi.org/10.46439/stemcell.1.005.